CaMKII (Ca 2 + /calmodulin-dependent kinase II) is a serine/threonine phosphotransferase that is capable of longterm retention of activity due to autophosphorylation at a specific threonine residue within each subunit of its oligomeric structure. autophosphorylation levels and greatly reduces the catalytic activity towards an exogenous substrate (autocamtide-3), whereas the S26A mutation has no effect. These data combined with molecular modelling indicate that a negative charge at Ser 26 of CaMKII γ inhibits the catalytic activity of the enzyme towards its autophosphorylation site at Thr 287 most probably by blocking ATP binding. We propose that Ser 26 phosphorylation constitutes an important mechanism for switching off CaMKII activity.
INTRODUCTION
CaMKII (Ca 2 + /calmodulin-dependent kinase II) is a ubiquitously expressed serine/threonine protein kinase, which functions as a multimeric holoenzyme consisting of 12 monomers [1, 2] . The holoenzyme is organized into a ring-like structure and the catalytic/autoregulatory component of each subunit is attached to the hexameric ring by a stalk-like extension. Two such hexameric rings stacked on top of each other form the dodecameric holoenzyme. The association domain forms the core of the holoenzyme, whereas the catalytic activity resides in the peripheral 'foot'-like structures [1, 3] 
Abbreviations used: 2D, two-dimensional; CaM, calmodulin; CaMKII, Ca 2 + /calmodulin-dependent kinase II; DMEM, Dulbecco's modified Eagle's medium; DTT, dithiothreitol; FBS, fetal bovine serum; LC-MS/MS, liquid chromatography tandem MS; PKA, protein kinase A; PSS, physiological saline solution; SCP3, small C-terminal domain phosphatase 3; TCA, trichloroacetic acid; VSMC, vascular smooth muscle cell; wt, wild-type. 1 To whom correspondence should be addressed (email kmorgan@bu.edu).
Thr
287 is the primary site responsible for regulation of the autonomous activity of CaMKII [4] . Activation and Ser 350 ) ( [6] , but see [6a] , [7] [8] [9] ); however, only for some of them (Thr 305 , Thr 306 and Thr 254 ) are the functional consequences known [8, 10, 11] . The most curious of these additional sites is Ser 26 due to its location in the ATP-binding site. This phosphorylation site is the main focus of the present work. Four isoforms of CaMKII are known: α, β, γ and δ [12] . Alternative splicing of these gene products result in multiple variants [13] . The α and β isoforms have been extensively studied and are expressed primarily in neuronal tissues and brain [12, 14] . They are reported to play a crucial role in behaviour and memory through their influence on LTP (long-term potentiation) at PSDs (postsynaptic densities) [15] .
Unlike α and β isoforms, δ and γ isoforms are, in general, ubiquitously expressed [16] . The CAMK2D (encoding δ CaMKII) gene products have been extensively studied in cardiac muscle [15] [16] [17] [18] . The γ isoform has been studied in the vasculature [11, [19] [20] [21] and in many other tissue types [12, 16, 22] . The δ isoform has been linked with proliferative VSMCs (vascular smooth muscle cells), whereas the γ isoform appears to be more closely linked with non-proliferative contractile VSMCs [20, 23] . Vascular tone is maintained by the contractility of differentiated VSMCs. CaMKII has been shown to be a significant regulator of vascular tone as shown by experiments with antisense knockdown of CaMKII and small molecule inhibitors [20, 24] .
Our group has isolated six CaMKII γ variants, C-1, C-2, G-1, G-2, B and J, from an aorta smooth muscle cDNA library [19] . The main differences between these variants occur in the segment that connects the catalytic/regulatory domain with the association domain. The C-1 and C-2 variants lack variable region 1 (V1) and variable region 2 (V2). Furthermore, C-2 lacks an eight amino acid sequence (residues 23-30) that forms part of the ATP-binding motif of the catalytic domain. Interestingly, this variant displays defective autophosphorylation at Thr 287 , but surprisingly is still able to phosphorylate an exogenous substrate [19] . Our laboratory has previously reported that this deleted sequence contains a serine residue (Ser 26 ), as determined by LC-MS/MS (liquid chromatography tandem MS) of the recombinant C-1 variant, is autophosphorylated when the kinase is activated by Ca 2 + /CaM [7] . In the present paper, we provide evidence that phosphorylation of CaMKII γ at this novel autophosphorylation site, Ser 26 , occurs in vascular tissue and is important for the termination of the sustained activity of CaMKII γ .
EXPERIMENTAL

Tissue preparation
Freshly isolated aorta from the ferret was prepared as previously described [11] . Stimulated or unstimulated aorta rings were quick-frozen in 5 mM DTT (dithiothreitol) with 10 % (w/v) TCA (trichloroacetic acid) in solid CO 2 /acetone and stored at − 80
• C for later use. All procedures have been approved by the Boston University Institutional Animal Care and Use Committee. The animals were maintained in a manner consistent with the NIH Guide for the Care and Use of Laboratory Animals and were obtained and used in compliance with federal, state and local laws. Physiological experiments were performed using a PSS (physiological saline solution) as described previously [20] ; 51 mM PSS with 51 mM NaCl replaced by KCl was used as depolarizing stimulus.
2D (two-dimensional) gels and immunoblotting
Samples were quick frozen in a solid CO 2 /acetone slurry containing DTT and TCA, and washed in acetone with 5 mM DTT. IEF (isoelectric focusing) tube gels and PAGE gels were prepared as previously described [19] . Ampholytes used were 3-10 and 5-6. Gels were transferred on to PVDF membranes and processed using a standard immunoblotting protocol. Blots were probed with a total CaMKII γ antibody, a G-2 CaMKII γ antibody and a vimentin antibody (see the Antibodies and reagents section • C for 30 min, then 500 μl of Biomol Green reagent (see the Antibodies and reagents section) was added and the samples were incubated for another 30 min at 30
• C. The extent of the reaction was calculated from the absorbance at 620 nm according to the Biomol Green reagent protocol. 
Antibody generation
Cell culture
COS-7 cells were maintained in DMEM (Dulbecco's modified Eagle's medium) culture medium supplemented with 4.5 
D-glucose, L-glutamine, 110 mg/l sodium pyruvate, 50 units/ml penicillin, 50 μg/ml streptomycin and 10 % (v/v) FBS (fetal bovine serum). His-tagged CaMKII γ C-1 and mutant cDNAs in pcDNA4/HisMax TOPO vector were transfected into COS-7 cells by using Lipofectamine TM reagent (Invitrogen). The amount of Lipofectamine TM and the plasmid were titrated for the experiment according to the Lipofectamine TM protocol using OPTI-MEM to increase the transfection efficiency. Plasmids were expressed for 24 h. Cells were lysed on ice with phosphate lysis buffer (20 mM sodium phosphate, 140 mM NaCl 2 , 3 mM MgCl 2 , 0.5 % Nonidet P40, 1 mM DTT, 1× protease inhibitor mixture and a standard immunoblotting technique was followed.
Site-directed mutagenesis C-1 cDNA in pcDNA4/HisMax TOPO was used to mutate Ser 26 to alanine (A) or aspartic acid (D) using the primers S26A-sense 5 -GCAAGGGTGCTTTCGCTGTGGTCCGCAGG-3 , S26A-antisense 5 -CCTGCGGACCACAGCGAAAGCACCCTTGC-3 , S26D-sense 5 -GGCAAGGGTGCTTTCGATGTGGTCC-GCAGGTG-3 and S26D-antisense 5 -CACCTGCGGAC-CACATCGAAAGCACCCTTGCC-3 . QuikChange II XL sitedirected mutagenesis kit was used according to the manufacturer's protocol. Mutations were confirmed later with sequencing by Eurofins MWG Operon.
Dot-blot kinase assay
A solution containing 50 mM Pipes (pH 7.0), 10 mM MgCl 2 , 10 mM CaCl 2 , 0.5 μg/ml CaM, 20 μM autocamtide-3 (H 2 NLys-Lys-Ala-Leu-His-Arg-Gln-Glu-Thr-Val-Asp-Ala-Leu-COOH), 0.225 mM ATP, 0.1 mg/ml BSA, 1× protease inhibitor and 5 μl of CaMKII was used in a 50 μl kinase-assay reaction. The reaction was stopped using 50 mM EDTA. Next, the peptide was separated from the kinase using 300 kDa cut-off spin filtration columns. Then 2 μl of the autocamtide-3 fraction of the assay were spotted onto a nitrocellulose membrane. Dot blots were blocked and analysed with anti-total phosphothreonine antibody (see the Antibodies and reagents section). In parallel experiments under identical conditions, negative controls, consisting each of no CaM, no CaM and no ATP, and BSA only, were tested with CaMKII wt (wild-type) and resulted in no signal.
Molecular modelling
For modelling the catalytic domain of CaMKII γ C-1 isoform, we have used the Swiss Model server (http://swissmodel. expasy.org/) [25] [26] [27] . The model was built using the structure of PKA (protein kinase) (PDB entry 1ATP) as a template. Residues 12-261 of C-1 were aligned with residues 42-282 of PKA. Rebuilding of the missing loops was done by the Swiss Model server. Co-ordinates for ATP and two Mn 2 + ions present in 1ATP were introduced into the C-1 model and the structure was optimized with Phenix [28] . Ser 26 was either phosphorylated or mutated to aspartic acid using COOT [29] and the structures were energy optimized without ATP using Phenix. 
Antibodies and reagents
The antibodies used in present study were rabbit antitotal CaMKII γ (1:250 dilution; Upstate/Millipore); rabbit anti-CaMKII γ G-2 [21] (1:500 dilution); mouse antivimentin antibody (1:400 dilution; Sigma); mouse anti-tubulin (1:1000 Cell Signaling); mouse anti-His-tag antibody (1:5000 dilution; Cell Signaling); rabbit anti-phosphothreonine antibody (1:500 dilution; Cell Signaling); mouse anti-pThr 287 antibody (Millipore); rabbit anti-CaMKII G-2 (1:500 dilution) [21] ; fluorescently labelled secondary antibodies (1:1000 dilution; LI-COR Biosciences). DMEM (Gibco), FBS (Gibco), OPTI-MEM (Invitrogen), protease inhibitor (Roche), QuikChange II XL (Stratagene), Lipofectamine TM (Invitrogen), Biomol Green reagent (Biomol International). cDNA sequences are from ferret.
Statistics
Unless indicated otherwise, significance of difference between two individual datasets was taken at P < 0.05 by a two-tailed paired Student's t test. Data are presented as means + − S.E. 
RESULTS
2D gels indicate multiple post-translational modifications of CaMKII γ in vascular tissue
To determine whether CaMKII γ variants are phosphorylated at multiple sites in vascular tissue, we analysed vascular homogenates by 2D gel electrophoresis followed by immunoblotting, using vimentin as a reference protein. Vimentin has a calculated pI of 5.1 and post-translationally modified forms of vimentin from human arterial smooth muscle cells are known to run within the range 3.8-4.9 ( Figure 1A ) in 2D maps [30] . As shown in Figure 1(A) , the calculated pIs of CaMKII γ variants cover the range 6.8-7. 3 . Figure 1 (B) shows a Western blot of all CaMKII γ variants separated by 2D gel electrophoresis and stained with an anti-total CaMKII γ antibody. In addition to probing with the total CaMKII γ antibody (rabbit polyclonal, red channel), we subsequently co-labelled the blot with a CaMKII γ G-2 variantspecific antibody (also a rabbit polyclonal, red channel) to confirm the identity of CaMKII spots on the 2D gel. The CaMKII γ G-2-specific antibody typically stains an oval apparently containing several forms of the G-2 variant on the blot ( Figure 1C , arrow). The same membrane was probed with an anti-vimentin antibody (monoclonal mouse, green channel) as a reference protein ( Figures 1A and 1D ). previously identified [7, 19] Figure 3E ), suggesting that phosphorylation of Ser 280 is not regulated under these physiological conditions. As a positive control, a pThr 287 -specific antibody was used to confirm CaMKII activation in these tissues ( Figure 3G ).
Phosphorylation of Ser 26 is regulated by depolarization in vascular tissue
Ser 26 is located within a conserved stretch of nine residues (LGKGAFSVV) that constitute the upper lid of the ATPbinding site in the canonical kinase fold (bold letters indicate conserved residues). To test the physiological importance of CaMKII phosphorylation at Ser 26 during vascular depolarization, a phosphospecific antibody against Ser 26 was raised using the phosphopeptide sequence H 2 N-LGKGAFS(p)-VVRRCVKKTSTQE-COOH. Antibody specificity was tested by comparing preimmune and immune serum staining of aorta homogenates. A signal at the expected molecular mass was detected only with immune serum ( Figure 3C ). The identity of the band was confirmed with a pCaMKIIThr 287 -specific antibody (results not shown). Next, the phosphopeptide used to raise the antibody was mixed with the antibody in a competition assay. As shown in Figure 3(D) , the competing peptide decreased the antibody signal in a concentration-dependent manner.
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The phosphomimic CaMKII S26D mutant cannot phosphorylate exogenous CaMKII Thr 287 substrate
To investigate whether the observed inhibition of Thr 287 phosphorylation in the S26D mutant is due to a direct inhibition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . of kinase activity, an in vitro kinase assay was performed using a 13-amino-acid peptide containing Thr 287 (autocamtide-3) as a substrate. His-tagged purified recombinant CaMKII wt, the S26D mutant and the S26A mutant were used in vitro dot-blot kinase assays containing 20 μM autocamtide-3, 5 μg/ml CaM and 10 mM CaCl 2 to activate the kinase. The phosphorylated peptide was separated from the holoenzyme (∼680 kDa) using a sizing spin column. As shown in Figure 4 (C) and is quantified in Figure 4(D) , the S26D mutant caused negligible threonine phosphorylation of the exogenous peptide even though significant amounts of peptide phosphorylation were seen with the S26A mutant and wt kinase. The S26A mutant showed significantly more activity in phosphorylating the substrate peptide than did wt kinase, suggesting that autophosphorylation of the wt kinase leads to less than the maximal possible kinase activity.
Taken together, these results indicate that the negative charge on Ser 26 of CaMKII γ introduced by the mutation or by autophosphorylation of wt kinase inhibits the catalytic activity of the enzyme towards its autophosphorylation site at Thr 287 .
Structural interpretation of the CaMKII inhibition by Ser 26 phosphorylation
In the absence of a three-dimensional structure of CaMKII phosphorylated on Ser 26 we used homology modelling to explain a plausible mechanism for the kinase inhibition by Ser 26 phosphorylation or S26D mutation. Ser 26 is located in a stretch of residues that form the first two β-strands and the connecting loop of the β domain in the canonical kinase fold. We refer to this segment as the 'upper lid' of the ATP-binding site because these residues make extensive interactions with the ATP molecule, specifically with the triphosphate moiety, as observed, for example, in the structure of the PKA-ATP complex [32] . Glycine is the most commonly found amino acid at the position corresponding to CaMKII Ser 26 . This semi-conserved glycine residue plays an important role in positioning the triphosphate moiety for catalysis by making a strong hydrogen bond with one of the β-phosphate oxygen atoms. Besides the serine residue found in all CaMKII isoforms there are also alanine and histidine found among the very few substitutions at this position in the kinase superfamily. Thus, there must be a strong evolutionary selection at this position and it is probable that the glycine→ serine substitution plays an important function specific for CaMKII. To evaluate the possible consequences of introducing an acidic group at this position, we have modelled the wt CaMKII γ C-1 isoform, its phosphorylated form and the S26D mutant based on the structure of PKA (PDB entry 1ATP). We found the PKA structure to be a better template for the modelling than the recently published structure of CaMKII γ isoform (PDB entry 1V7O), because in the latter the loop containing Ser 26 is disordered due to the absence of the triphosphate moiety in the bound inhibitor. In the modelled structure of C-1, all the interactions between the protein and ATP are well preserved including a correct geometry and bond lengths for the bound metal (Mn 2 + ), which positions the γ phosphate for catalysis. Therefore we are confident that our model has all the essential features of Figure 5 Atomic model depicting a role for Ser 26 phosphorylation (A) Alignment with the protein whose structure was used for modelling and marking the residues that were used for structural homology alignment residues involved in ATP binding are shown in red (B) On the left, the front and the back view (rotated 180
• on the y-axis) of the modelled C-1 wt structure with ATP . On the right, close view of atomic structure of unphosphorylated Ser 26 , S26D and phosphorylated Ser 26 (Ser 26 -PO4) on modelled CaMKII C-1 structure with ATP . Atomic colour code: Phosphate (orange), oxygen (red), carbon (green), nitrogen (blue). Structures drawn using the PyMOL Molecular Graphics System, version 1.2r3pre, Schrödinger.
the CaMKII structure. The modelled structures suggest that the negatively charged side chain carboxy group of the aspartic acid residue or the phosphate attached to the serine side chain oxygen would clash with the β-phosphate group of ATP, thus either sterically interfering with the catalysis, i.e. with the transfer of the γ phosphate to a substrate such as Thr 287 or inhibiting the ATP binding ( Figure 5) . Furthermore, owing to the orientation of the Ser 26 side chain towards the catalytic cleft, and its position close to the β-phosphate of the bound ATP, this side chain is not readily accessible to an external kinase molecule. It appears that the phosphorylation of Ser 26 most probably occurs by an intramolecular mechanism. We propose that phosphorylation of Ser 26 works as an internal break that allows the switching off the constitutively active oligomeric CaMKII.
DISCUSSION
CaMKII Ser 26 is conserved in all CaMKII isoforms from mammals through to Drosophila, but not in yeast ( Figure 6 ). This points to an important functional role for the site. Additionally, Ser 26 is known to be part of the ATP-binding motif of the catalytic domain [33] as shown in Figure 5 (A). In the current study, we have demonstrated, first, that Ser 26 in CaMKII γ is regulated by phosphorylation during depolarizing stimuli in blood vessels and, secondly, by mutagenesis that phosphorylation at this site switches off Ca 2 + -activated kinase activity, preventing prolonged kinase activity. Ser 26 is located within a conserved stretch of nine residues (LGKGAFSVV) that constitutes the upper lid of the ATP-binding site in the canonical kinase fold. The phosphomimic mutation of CaMKII (S26D) causes a dramatic decrease in Thr 287 phosphorylation levels, while the S26A mutation has no effect. The decreased Thr 287 autophosphorylation in the oligomer could be due to a number of possible mechanisms. To directly test the possibility that the Ser 26 phosphomimic impairs the activity of the catalytic cleft, we used an exogenous substrate known as autocamtide-3, and found, indeed that the phosphomimic kinase (S26D) has an impaired catalytic activity.
One interesting issue that arises is that, when whole vascular tissue homogenates are probed in immunoblots for phosphorylation of CaMKII Thr 287 and Ser 26 phosphorylation (Figure 3 ) phosphorylation of both sites appears to coexist during steady-state depolarization of the tissue. This is in marked contrast with the results with the phosphomimic mutants in recombinant homooligomers (Figure 4) . Tissue-wide depolarization of cells leads to a non-selective Ca 2 + rise in stimulated VSMCs, which is expected to globally activate a large pool of CaMKII. Global activation of a promiscuous kinase is unlikely to be advantageous to the cell and would be expected to disrupt targeting of specific signalling pathways. Thus, Ser 26 phosphorylation might be a mechanism controlling the spatially distributed CaMKII activity during a rapid Ca 2 + flux into the VSMCs. CaMKII in which either Ser 26 or Thr 287 is phosphorylated may occur in different cellular pools. This concept is consistent with what we know about the targeting of the G-2 variant of CaMKII γ in smooth muscle and its interaction with SCP3. SCP3 is a small PP2C (protein phophatase 2C)-type C-terminal domain phosphatase present in vascular smooth muscle. CaMKII γ G-2 and SCP3 are co-localized on a central vimentin-and α actinin-containing cytoskeleton in unstimulated VSMCs; however, once the cell is depolarized G-2 and SCP3 separate and G-2 is targeted to the cell surface [21] . SCP3 is of interest since it decreases total 32 P incorporation into CaMKII by autophosphorylation but does not dephosphorylate Thr 287 [7] . We now show that it dephosphorylates Ser 26 and Ser 280 preferentially, with no activity towards other sites including Thr 287 ( Figure 3) . Thus, when CaMKII and SCP3 co-localize, SCP3 would keep Ser 26 dephosphorylated but when they separate, Ser 26 would be phosphorylated by the still active kinase and would then inhibit kinase activity, producing a 'sleeping' pool of CaMKII at the cell surface.
We have previously reported that the B and J variants of the CaMKII γ isoform 'autodephosphorylate' [19] . Others have described a similar phenomenon and attributed it to a reverse of the activation mechanism [34] , but this mechanism did not fully explain our observations. The effect of Ser 26 phosphorylation to inhibit kinase activity could well explain these previous observations as well. Thus, if Thr 287 phosphorylation is a mechanism for 'remembering' phosphorylation [35] , then Ser 26 phosphorylation may be a mechanism for 'forgetting'.
Taken together, we demonstrate here that there are novel autophosphorylations in vitro and in vivo on CaMKII, and Ser 26 is one of them. We have discovered that a Ser 26 phosphomimic CaMKII has impaired Thr 287 phosphorylation and reduced catalytic activity, probably due to inhibition of ATP binding. This action constitutes an important mechanism for switching the kinase off, possibly in a spatially targeted manner. 
